Compare Neurocrine Biosciences Inc (NBIX) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Annaly Capital Management, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Annaly Capital Management, Inc. trades at $22.83 (market cap $17.12B). The key difference: Neurocrine Biosciences Inc and Annaly Capital Management, Inc. are close in size by market cap, and Annaly Capital Management, Inc. pays a 13.2% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NLY | |
|---|---|---|
Market Cap | $15.77B | $17.12B |
Sector | Health | Financials |
52-Week High | $185.50 | $24.40 |
52-Week Low | $123.10 | $20.21 |
Enterprise Value | $15.78B | — |
Dividend Yield | — | 13.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
NLY trades at $22.72, down 0.39% today, with a technical bearish signal but strong fundamentals including a P/E of 5.49 and ROE of 20.66%. Recent earnings beats and a $0.75 dividend highlight operational strength, though cash flow volatility and high leverage pose risks.
Outlook remains positive with analyst consensus at Buy (57% of 28 analysts) and a $24.33 price target, offering ~7% upside. Key risks include interest rate sensitivity and debt levels, but diversified mortgage assets and consistent dividend coverage support income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
